Loading...
•
Dec 31, 2025
Kiniksa Q4 2025 Earnings Report
Kiniksa reported strong fourth quarter 2025 growth driven by ARCALYST, generating net income and significantly increasing cash balances year-over-year.
Key Takeaways
Kiniksa generated total revenue of 202127000 dollars in Q4 2025, up from 122536000 dollars in Q4 2024, driven entirely by ARCALYST. The company reported net income of 14199000 dollars compared to a net loss in the prior year, while maintaining a strong cash position of 414074000 dollars.
Q4 2025 total revenue increased to 202127000 dollars from 122536000 dollars year-over-year.
Net income was 14199000 dollars compared to a net loss of 8888000 dollars in Q4 2024.
ARCALYST Q4 net product revenue reached 202127000 dollars.
Cash, cash equivalents and short-term investments totaled 414074000 dollars at year end.
Revenue by Segment
Forward Guidance
Kiniksa expects 2026 ARCALYST net product revenue between 900000000 and 920000000 dollars and anticipates remaining cash flow positive on an annual basis.
Positive Outlook
- 2026 ARCALYST net product revenue expected between 900000000 and 920000000 dollars.
- Operating plan expected to remain cash flow positive annually.
- Strong cash balance of 414074000 dollars.
- Ongoing Phase 2/3 development of KPL-387 with data expected in second half of 2026.
- Phase 1 trial of KPL-1161 planned by end of 2026.
Challenges Ahead
- Reliance on ARCALYST as primary revenue driver.
- Ongoing collaboration expense obligations.
- Clinical development risks for KPL-387 and KPL-1161.
- Exposure to regulatory and reimbursement changes.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...